Screener
Viridian Therapeutics, Inc. VRDN Business Segments — Segment selling, general and administrative expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept vrdn:SellingGeneralAndAdministrativeExpenseExcludingShareBasedCompensationExpense.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
| Line item | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | 2025 |
|---|---|---|---|---|
| Segment research and development expense (a) | $64,189 | $81,401 | $135,933 | $152,439 |
| Segment selling, general and administrative expense (a) | 45,262 | 14,483 | 76,317 | 27,047 |
| Share-based compensation expense (see Note 11) | 16,984 | 10,844 | 30,374 | 21,064 |
| Total operating expenses, excluding depreciation expense | 126,435 | 106,728 | 242,624 | 200,550 |
| License revenue | 180 | — | 186 | — |
| Other items (b) | 504 | (5,993) | (10,790) | (12,903) |
| Consolidated net loss | $127,119 | $100,735 | $232,020 | $187,647 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Viridian Therapeutics, Inc.'s business segments — segment selling, general and administrative expense?
- Viridian Therapeutics, Inc. (VRDN) reported business segments — segment selling, general and administrative expense of $45.26M in Q2 2026.
- How has Viridian Therapeutics, Inc.'s business segments — segment selling, general and administrative expense changed year-over-year?
- Viridian Therapeutics, Inc.'s business segments — segment selling, general and administrative expense increased by 212.5% year-over-year, from $14.48M to $45.26M.
- What does business segments — segment selling, general and administrative expense mean?
- This metric captures the costs associated with selling, marketing, and general administrative functions within the business segment, excluding share-based compensation. It reflects the operational overhead required to support the segment's commercial and corporate infrastructure. Monitoring this helps assess the efficiency of the segment's non-research operational spending.
Ask your AI about Viridian Therapeutics, Inc.'s business segments — segment selling, general and administrative expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude